A
Andrew Lister
Researcher at Queen Mary University of London
Publications - 46
Citations - 6352
Andrew Lister is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Follicular lymphoma & Rituximab. The author has an hindex of 23, co-authored 46 publications receiving 5840 citations. Previous affiliations of Andrew Lister include St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy of an intensive post-induction chemotherapy regimen for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, given predominantly in the out-patient setting
Tamara Intermesoli,Shekhar Krishnan,Finlay MacDougall,Michael Jenner,Andrew Lister,Ama Z. S. Rohatiner +5 more
TL;DR: Evaluation of outcome of patients treated with an intensive regimen based on that used in the German national trials, but adapted in order to enable treatment to be given mainly on an out-patient basis, once complete remission (CR) had been achieved.
Journal ArticleDOI
Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.
Gilles Salles,John Catalano,Pierre Feugier,Fritz Offner,Reda Bouabdallah,Dolores Caballero,Pauline Brice,Lars Moller Pedersen,Corinne Haioun,David Belada,Alain Delmer,David Simpson,Hervé Tilly,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai,Christophe Fermé,Maria Gomes da Silva,Catherine Sebban,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Armando López-Guillermo,John F. Seymour,Luc Xerri +27 more
TL;DR: The PRIMA results indicate that rituximab maintenance should be considered in all follicular lymphoma patients who have responded to first line immunochemotherapy, resulting in improved progression free survival and complete response rates.
Journal ArticleDOI
An Immunohistochemical Score Based On CD68 and FOXP3 Expression In the Tumour Microenvironment at Diagnosis Defines Prognostic Groups In Both Early and Advanced Stage Classical Hodgkin Lymphoma
Paul Greaves,Andrew Clear,David Andrew Owen,Finlay MacDougall,Andrew Wilson,Andrew Lister,Maria Calaminici,John G. Gribben +7 more
TL;DR: A prognostic score based upon expression of both FOXP3 and CD68 in the CHL microenvironment was developed which defined poor and good risk groups in both early (Stages I and IIA) and advanced stage disease, including a 'poor risk' early stage group with 25% FFTF and a ‘good risk' advancedStage group with 90% F FTF.
Journal ArticleDOI
Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up.
Ama Z. S. Rohatiner,Matthew L. Smith,Orietta Spinelli,Alessandro Rambaldi,Renato Bassan,Eros Di Bona,Francesco Rodeghiero,Roberto Raimondi,Magnus Björkholm,Steve Johnson,Adrian C. Newland,Jamie Cavenagh,Finlay MacDougall,Rachel Waters,Jude Fitzgibbon,Tiziano Barbui,Andrew Lister +16 more
TL;DR: A recently published population-based study showed an improvement in 5-year relative survival of patients with acute myeloid leukaemia (AML) presenting between 1971 and 2006, with a current minimum follow-up of 14 years, highlighting the role of intensive consolidation.
Journal ArticleDOI
Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan (Zevalin®) as Consolidation of First Remission in Patients with Advanced Stage Follicular Lymphoma: A ’Real-Time’ MBR RQ-PCR Analysis.
Lindsey K. Goff,Karin E. Summers,Sameena Iqbal,Jens Kuhlmann,Michael Kunz,Anton Hagenbeek,Andrew Lister,Ama Z. S. Rohatiner +7 more
TL;DR: The randomized phase 3 First-line Indolent Trial (FIT) was conducted in newly diagnosed patients with stage III or IV follicular lymphoma to investigate the use of 90Y-ibritumomab tiuxetan (Zevalin) given as consolidation of first complete (CR/CRu) or partial remission (PR).